BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure.
Join BioNet at #ESPID2026
E-Poster #2837
Addressing waning immunity: Immunogenicity and pooled safety of a PTGen-containing recombinant pertussis vaccine across populations
Presented by Dr. Giuseppe Del Giudice
Europeans in the European Union (EU) may soon have the choice to get vaccinated against whooping cough with a new pertussis-only vaccine that is about to hit the market.